WebAug 7, 2024 · Pamrevlumab, a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor (CTGF), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. WebMonoclonal Antibody for studying CTGF. Cited in 36 publications. Validated for Western Blotting, Immunofluorescence (Immunocytochemistry). Highly specific and rigorously validated in-house, CTGF (D8Z8U) Rabbit Monoclonal Antibody (CST #86641) is ready to ship. ... Antibody Dilution Buffer (1X PBS / 1% BSA / 0.3% Triton X-100): To prepare 10 …
Facebook - National Cancer Institute
WebDec 7, 2024 · A particularly exciting paper, recently published in Lancet Respiratory Medicine (Richeldi et al. 2024), described the recently successful Phase II clinical trial, PRAISE, which was a randomised, double-blind, placebo-controlled trial of the anti-CCN2 antibody FG-3019 (pamrevlumab) in idiopathic pulmonary fibrosis (IPF) … WebPamrevlumab is in Phase 3 clinical studies for the treatment of idiopathic pulmonary fibrosis, Duchenne muscular dystrophy, and locally advanced pancreatic cancer. … simplest form 5/10
KR102512597B1 - 항-cMet 항체 약물 컨쥬게이트 및 그들의 이용 …
Webantibody cancer antibodies Prior art date 2016-05-17 Application number KR1020247033500A Other languages English (en) Other versions KR20240137158A (ko Inventor 에드워드 비. 라일리 WebApr 13, 2024 · The identification of tissue-specific promoters for gene therapeutic constructs is one of the aims of complex tumor therapy. The genes encoding the fibroblast activation protein (FAP) and the connective tissue growth factor (CTGF) can function in tumor-associated stromal cells but are practically inactive in normal adult cells. Accordingly, the … WebCtgf Antibody, Anti-CTGF antibody produced in rabbit. Tested Applications: immunohistochemistry 1:20- 1:50, immunofluorescence 1-4μg/mL, immunoblotting None. … simplest form method of thinking is